- ALSO READ
India’s largest drug maker Sun Pharmaceutical Industries has posted a 43 per cent rise in net profit for the first quarter of the current fiscal year, to Rs 2,061 crore, beating street estimates, riding on robust sales across India, US and emerging markets. The firm’s gross sales were up 10.1 per cent year-on-year (YoY) to Rs 10,644 crore during the quarter, from Rs 9,719 crore a year ago.
Excluding the exceptional items of Q1 last year, the adjusted net profit was up 4.1 per cent.
EBITDA for the quarter came in at Rs 2,884.4 crore (including other operating revenues), and at a margin of 26.8 per cent.
The company said excluding sales of Covid-19 products, the overall sales are up by about 14 per cent. The India formulations business was up 13 per cent on a like-to-like basis, excluding Covid-19 product sales of Q1 last year. “On a reported basis, the growth is 2.4 per cent over Q1 last year,” the company said.
US formulation sales came in at $420 million, up 10.7 per cent over Q1FY22, while emerging market formulation sales were $245 million (12.6 per cent). Rest of world formulation sales came in at $190 million (2.6 per cent).
Dilip Shanghvi, managing director of the company, said, “For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our specialty business and all-round growth across markets.”
The growth in Q1FY23 was led by the rise in Sun Pharma’s specialty business.
“Specialty business has grown 29 per cent, driven by Ilumya, Cequa, Odomzo and Winlevi. Our India business continues to grow faster than the market, leading to an increase in market share. We have been able to report healthy margins despite rising costs. We continue to focus on expanding our global specialty business, growing all our businesses and improving our market share,” Shanghvi said.
He added that specialty R&D constituted 21 per cent of overall R&D. There were four specialty molecules, which are in clinical trials now.
India formulation sales accounted for about 32 per cent of total consolidated sales while the US accounted for over 30 per cent. Sun Pharma improved its market share to 8.5 per cent in India as of June 2022. There were no sales of Covid-19 drugs during Q1FY23 in India. In the US Winlevi, the specialty drug that got approval late last year, has seen 10,000 doctors prescribing it.
Sun Pharma’s Israeli subsidiary Taro posted Q1FY23 sales of $157 million and net profit of $14 million. Taro’s financials include the first full quarter of consolidation of the Alchemee acquisition.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
First Published: Fri, July 29 2022. 16:33 IST